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4Hepatology Division, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75206, USAThis article summarizes the current state of antiviral therapy of hepatitis B with special attention given to areas that
remain controversial or poorly deﬁned. Strict adherence to liver association practice guidelines may result in missed oppor-
tunities to treat patients with signiﬁcant underlying liver disease. In particular, recommended ALT thresholds may not
appropriately reﬂect disease activity or degree of ﬁbrosis. There is growing evidence that an alternative treatment para-
digm for preventing late-stage disease complications may be indicated in highly viremic patients with early life exposure to
hepatitis B. Pegylated interferon therapy is often a better choice for young to middle-aged patients with genotype A and B
because of the higher rate of HBeAg seroconversion and a greater chance for HBsAg seroconversion in both HBeAg-posi-
tive and -negative patients as compared to nucleoside analogs. Nucleoside analog monotherapy is the current standard of
care for many patients. However, long-term monotherapy results in resistance to a variable degree and sequential mono-
therapy may result in multi-drug resistant virus. Which patients would speciﬁcally beneﬁt from early combination therapy
also remains poorly deﬁned. The rapidity and robustness of the suppression of HBV DNA while on a nucleoside analog
should be monitored relatively early during treatment because it aﬀects treatment outcome and the rate of resistance.
While great progress has been made in treating hepatitis B, many important issues require further study.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Hepatitis B is a major global health problem. The
World Health Organization reports that there are more
than 400 million carriers in the world, approximately
75% of whom reside in Asia and the Western Paciﬁc
[1]. However, this disorder is not uncommon in Europe
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ferase; HIV, human immunodeﬁciency virus.patterns have led to substantial expansion of the num-
bers of cases of chronic hepatitis B in geographic regions
formerly considered to be of low prevalence.
Hepatitis B is the leading cause of liver cancer in the
world today and frequently leads to cirrhosis and liver
failure, particularly in individuals with early life acquisi-
tion. Although signiﬁcant progress has been made in the
area of vaccination, universal vaccination of children
and young adults has not yet been realized [2]. This
places tremendous importance on the development of
more eﬀective antiviral therapies.2. Goals of hepatitis B therapy
Current antiviral therapies are inadequate to eradi-
cate HBV infection. Thus, practitioners must settle onPublished by Elsevier B.V. All rights reserved.
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majority of cases. There are both short-term and long-
term goals of treatment. Short-term goals include
achieving the virologic endpoints of HBeAg seroconver-
sion and reduction in HBV DNA levels to below those
associated with liver disease as well as restoration of
serum aminotransferase levels to the normal range. Ide-
ally, patients should become HBV DNA undetectable
by PCR on therapy because persistent viremia has been
associated with a higher rate of failed response later on
as well as a greater chance of viral resistance. Long-term
goals such as improved survival, prevention of cirrhosis
and disease complications are even more important and
are achievable if treatment results in a durable virologic
response with the lowest level of HBV DNA possible.
HBsAg seroconversion occurs infrequently with current
antiviral therapy, but this is an important virologic end-
point since it is associated with a lower rate of relapse,
less chance for complications, and improved survival
in cirrhotic patients [3].3. Hepatitis B as an immune-based disorder
Hepatitis B is an immune-based disorder in which the
extent of disease as well as the frequency and quality of
virologic response are profoundly inﬂuenced by the
depth of the host immunologic response [4]. Following
acute infection, innate and adaptive immune responses
are insuﬃcient to achieve immunologic recovery in indi-
viduals destined to become HBV carriers [5]. Partial
preservation of this immune response, however, is essen-
tial to hepatocyte injury, progression of liver disease,
and response to therapy. The often repeated observation
that both interferon and nucleoside analogs are more
likely to be eﬀective in patients with moderate to severe
elevation of pre-therapy ALT reﬂects this dynamic inter-
action [6]. Unfortunately, the immunologic interface
between the host and the replicating virus also deter-
mines the extent to which liver disease becomes evident.
At any given stage of hepatitis B, there is a balance
between immunologic control and viral replication.
The triggering events for spontaneous reactivation and
clinical relapse of hepatitis B are poorly understood,Table 1
Reasons to consider less stringent indications for the treatment of hepatitis B
If patient has ALT <2  ULN If patien
 May be associated with signiﬁcant underlying liver disease
 Does not predict a lower risk of long-term complications
 Although a lower rate of HBeAg seroconversion, can still
respond following a ﬁnite course of therapy
 Lower rate of clinical progression in cases with advanced
ﬁbrosis when maintenance nucleoside analog therapy is
provided
 May fo
 Serum
 Poor c
hepatit
 Values
long-tebut are likely to be due to viral or host events that
change this balance [4].4. Treatment paradigms
The AASLD, EASL, and APASL associations have
each published guidelines for the management of hepa-
titis B in an attempt to provide objectivity and clarity
to treatment [7–9]. Because the guidelines are evidence-
based documents, recommendations are similar about
who to treat and how to administer antiviral therapy.
Each has similar thresholds for serum HBV DNA and
ALT beyond which treatment is recommended and
below which continued observation is suggested. HBV
DNA levels in excess of 100,000 copies or approximately
20,000 IU/mL have been proposed as thresholds for
treatment in both HBeAg-positive and HBeAg-negative
hepatitis B. Despite these seeming consistencies in the
treatment guidelines, there is mounting evidence that
strict adherence to arbitrary HBV DNA and ALT cut-
oﬀs would exclude many patients with signiﬁcant under-
lying liver disease from treatment (Table 1). For exam-
ple, the suggested HBV DNA threshold (20,000 IU/L)
identiﬁes the majority of patients, but not all, with active
liver disease. When HBV DNA was measured by poly-
merase chain reaction (PCR) in 165 Chinese patients,
89% of 27 persistently HBeAg-positive individuals had
serum HBV DNA levels above 20,000 IU/mL in all
available samples [10]. In the same study, 45% of
patients with HBeAg-negative CHB had values lower
than 20,000 IU/mL when testing was only performed
at the time of presentation. Greek investigators also
found that a level of 30,000 copies of HBV DNA
(approximately 6000 IU/mL) accurately distinguished
patients with HBeAg-negative CHB from inactive
HBsAg carriers in 93% of cases [11]. Serum HBV
DNA levels less than 30,000 copies were detected in
10.5% of 134 patients with HBeAg-negative CHB, and
values below 100,000 copies were found in 12.9%.
Finally, a large study also from Greece has recently
demonstrated that more than 10% of HBeAg-negative
hepatitis B patients with persistently or transiently
increased serum aminotransferase levels have serumwhen compared to current practice guidelines
t has HBV DNA <20,000 IU/mL
llow a ﬂare of ALT in patients with HBeAg-positive hepatitis B
HBV DNA ﬂuctuations are frequent in HBeAg-negative hepatitis B
orrelation of HBV DNA level with liver histology in HBeAg-negative
is B
of 104 copies (2000 IU/mL) may be associated with a higher risk for
rm complication such as cirrhosis and hepatocellular carcinoma
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the data indicate that some patients have active liver dis-
ease, even to the point of end-stage cirrhosis, and yet fall
below the HBV DNA thresholds suggested in the cur-
rent guidelines. This is particularly important in
HBeAg-negative hepatitis B where multiple determina-
tions of serum HBV DNA may be required to ensure
detection of spontaneous ﬂuctuations in viremia levels.
An even greater degree of concern has been raised
about the ALT cut-oﬀs that have been suggested in
the practice guidelines. The recommendation to consider
therapy in patients with ALT values at least twice the
upper limit of normal is primarily based on the observa-
tion of poor response rates to antiviral therapy in
patients with lower levels of ALT [6]. There are several
lines of evidence, however, that adherence to this thresh-
old would exclude a substantial number of patients from
therapy who might otherwise beneﬁt. For example,
serum aminotransferase elevations frequently ﬂuctuate
in HBeAg-negative hepatitis. In an Italian observational
study involving monthly monitoring of 164 untreated
patients, 45% had ALT ﬂares with periods of normaliza-
tion, and 20% had ﬂares superimposed upon persistent
ALT abnormalities [13]. There are also data to suggest
that serum aminotransferase level is not a good surro-
gate for underlying liver disease. As both ALT and
AST vary according to body mass index, gender, and
a number of other factors, it has been proposed that
the upper range of normal for ALT may be set too high
and values in the higher side of the normal range may be
abnormal for someone of lean body mass [14]. Indirect
evidence for this comes from a Korean study in which
liver-related mortality was evaluated against ALT and
AST testing in more than 140,000 persons. Mean BMI
for men was 23.4 and for women was 22.2. Compared
with values <20 IU/mL, the adjusted relative mortality
risks for an ALT of 30–39 were 9.5 in men and 6.6 in
women [15]. The results of a recent Chinese study also
emphasize how normal ALT levels may not accurately
reﬂect underlying histologic severity [16]. Investigators
biopsied 183 HBeAg-positive and 144 HBeAg-negative
patients with persistently normal ALT. Approximately
40 percent of the patients in each group had Pgrade 2
inﬂammation and 35% had Pstage 2 ﬁbrosis. Nor do
these ﬁndings appear to be linked to Asian ethnicity.
Recently, Iranian investigators found that ALT level
accurately predicted inﬂammation in HBeAg-positive,
but not HBeAg-negative patients [17]. In both groups,
ALT was an inaccurate marker of ﬁbrosis.
The potential fallibility in using the suggested HBV
DNA and ALT thresholds has also been underscored
by a longitudinal follow-up study of 3233 untreated
HBV carriers from Hong Kong [18]. When the risk of
disease complications such as liver failure and hepato-
cellular carcinoma was stratiﬁed according to ALT lev-
els on presentation, the cumulative risk was seen to behighest in patients with ALT values >1 to 2 the
ULN. Moreover, more than 70% of the patients were
already anti-HBe-positive and 44% had HBV DNA lev-
els equal to or less than 142,000 copies/mL, (approxi-
mately 28,000 IU/mL) at the time complications
developed. These data led the senior author to conclude
that treatment according to the suggested ALT thresh-
olds in the practice guidelines would exclude patients
with the highest risks for the development of complica-
tions. The study provides support for the hypothesis
that prolonged viremia at a relatively low level is the
most likely pathway leading to these complications in
HBeAg-negative patients [19].
In consideration of the above ﬁndings, a modiﬁed
treatment algorithm has been proposed by a panel of
expert hepatologists that endorses the treatment of
patients according to less stringent treatment thresholds
for HBV DNA and ALT [20]. The major areas of diﬀer-
ence from the practice guidelines of the liver associations
are in the proposal to use a lower HBV DNA threshold
(2000 IU/mL) for HBeAg-negative chronic hepatitis B
and to treat patients with any degree of ALT abnormal-
ity. The authors also suggest that the normal range for
ALT should be considered to be 19 IU/mL for women
and 30 IU/mL for men.
A recent survey of the international and national
membership of the American Association for the Study
of Liver Diseases also suggests that a substantial per-
centage of hepatologists are concerned that the ALT
and HBV DNA treatment thresholds in the practice
guidelines are too restrictive. When asked if they would
treat a patient with HBeAg-positive chronic hepatitis B
only if serum HBV DNA exceeded 20,000 IU/mL, 11%
of 241 members of the organization rejected this com-
pletely and 34% rejected it with some degree of reserva-
tion. When the same group was asked if they would treat
patients with high level viremia only if serum ALT was
greater than twice the ULN, 4% rejected this completely
and 13% rejected it with some degree of reservation [21].
Important to this study is that the responses were unli-
kely to have been aﬀected by a lack of clinical experience
with hepatitis B.5. Predicting long-term complications of chronic hepatitis
B by HBV DNA level: is a new paradigm indicated?
The predominant goal of antiviral therapy is to
extend life expectancy and prevent long-term complica-
tions. The therapeutic endpoints of phase III antiviral
therapy studies have been HBeAg seroconversion, sus-
tained reduction in HBV DNA, ALT improvement,
and improvement in histologic activity. For these end-
points to be most meaningful in clinical practice, how-
ever, one must assume that the response is durable
and there has been clear identiﬁcation of a level of
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gress and complications do not occur. Unfortunately, as
a surrogate marker of liver disease, there is substantial
variation in values for any given patient and no precise
levels have been identiﬁed below which serious disease
may not be found.
Large Asian cohort studies which depict the natural
history of hepatitis B over a 10–12 year period of fol-
low-up have recently shed new light on the relationship
of HBV DNA, HBeAg and ALT status to the risk of
developing late disease complications [22–29] (Table
2). These studies have clearly shown that HBV DNA
level at diagnosis is the best independent predictor of
future complications such as cirrhosis and hepatocellu-
lar carcinoma. More important, even values of 10,000
copies (2000 IU/mL) have been associated with an
increased risk of complications.
As multiple ﬂuctuations in HBV DNA levels occur
during longstanding infection, conﬁning the analysis to
one time screening levels does not properly address the
duration of active viremia as an important modiﬁer of
disease progression and complication frequency [30].
Further analysis in one of the large Asian cohort studies,
however, included serum HBV DNA values at the last
study visit or at the follow-up visit that preceded the
clinical detection of hepatocellular carcinoma [29]. This
study demonstrated that individuals who maintained
values equal to or greater than 100,000 copies
(20,000 IU/mL) during the 11-year follow-up had the
highest rate of hepatocellular carcinoma. Perhaps, more
important is that patients whose entry HBV DNA level
was greater than 100,000 copies but at last follow-up
had declined to less than 10,000 copies had an interme-
diate risk of hepatocellular carcinoma compared to
those who were persistently less than 10,000 copiesTable 2
Representative natural history studies in which serum HBV DNA is shown to
Population under study (reference number) Findings
 3582 untreated Taiwanese HBV carriers
recruited in 1991–1992, [23]
 Cumulative incidence o
 HBV DNA, rather than
 Increased relative risk o
 4841 Taiwanese HBV carriers recruited
in 1988–1992, [24]
 Progressive increase in
 HBV carriers with >4.2
with <3.6 log10
 Genotype C independen
 Nested case control analysis of 37 HCC
cases and 61 controls derived from
population of 3754 Asian Americans, [27]
 HBV DNA is a strongl
 Nearly 20% of HCC ca
 2354 Taiwanese HBV carriers
recruited in 1992–1993, [28]
 Progressive increase in
HBV DNA status (non
 1520 mainland Chinese HBV carriers
recruited in 1992–1993, [25]
 High viral load strongly
 17% of patients with un
at 10 years
 3653 Taiwanese carriers recruited
in 1991–1992, [29]
 Serum HBV DNAP 10
independent of HBeAg,and individuals persistently greater than 100,000 copies.
These data reaﬃrm that incidence rates for hepatocellu-
lar carcinoma occur along a biological gradient of HBV
DNA and suggest that inhibition of viral replication,
whether spontaneous or drug-induced, reduces the rate
of hepatocellular carcinoma. The ﬁndings also are con-
sistent with observations from a multicenter, random-
ized, controlled study in Asian HBV carriers which
demonstrated that long-term treatment with lamivudine
reduces the rate of disease progression and hepatocellu-
lar carcinoma in patients with advanced ﬁbrosis [31].
The large size and long-term follow-up in these natu-
ral history studies make the relationship between HBV
DNA level and the risk of liver disease complications
compelling. This also points to a need for a diﬀerent
approach to treatment in patients infected during early
life. On the basis of these data, it has been suggested that
long-term nucleoside analog treatment be administered
to patients with prolonged detectable viremia and mildly
elevated ALT [18–20,32]. This may even apply to lean
patients with high normal ALT (<.5  ULN-1  ULN)
since this group of patients has higher viral load than
those with low normal ALT values and appear to
more frequently enter into the immune clearance phase
[33–35]. The intent of this new therapeutic paradigm
would be to reduce the rate of long-term complications
by continuous viral suppression to the lowest possible
HBV DNA level. Such a strategy would be at odds with
practice guideline recommendations as to when to initi-
ate therapy. Furthermore, stopping rules based upon
achievement of endpoints like HBeAg seroconversion
or prolonged non-detectability of HBV DNA by PCR
would no longer apply. Instead, maintained suppression
of HBV replication during treatment would assume
overriding importance.predict late complications or mortality in chronic hepatitis B
f cirrhosis increases with HBV DNA level
HBeAg status or ALT, is the strongest predictor of cirrhosis
f cirrhosis starting with HBV DNAP 104 < 105 copies/mL
HCC incidence starting with HBV DNA level of 104 copies or greater
log 10 copies had 2- to 7-fold greater risk of HCC than those
tly and additively associated with increased risk of HCC
y correlated with risk of HCC
ses occurred in group with baseline HBV DNA level <105 copies
HCC-related mortality and liver disease mortality according to
-detectable, >1.6  103  <105 copies; >105 copies)
associated with increased risk of liver disease 10 years later
detectable (<3  104) or >3  104  <105 copies/mL had cirrhosis
,000 copies/mL is strong independent predictor of HCC
ALT, and cirrhosis
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6.1. Mechanisms of action
Treatment with alpha interferon results in an antivi-
ral state due to induction and expression of intracellular
genes and the functional activation of a variety of cellu-
lar proteins [36]. Interferon alfa also stimulates cell med-
iated immune responses against HBV which in turn
results in the destruction of infected hepatocytes. Early
clinical studies with standard interferon emphasized
the immunoregulatory properties of this drug [37,38].
With the advent of the more potent pegylated forms of
interferon, clinical trials have tended to emphasize the
antiviral activity of interferon [39–42]. The heavy
emphasis placed on the ability of interferon to suppress
HBV replication, rather than its immune enhancing
activity, is attributable to poor understanding of immu-
nologic events occurring during treatment and a lack of
standardized and readily available means of immuno-
logic testing. It has been demonstrated that ALT ﬂares
occurring during treatment with standard interferon
are predictive of HBeAg loss and sustained reduction
of HBV DNA, and the magnitude of these ﬂares also
has been shown to predict virologic response in the pres-
ence of relatively high levels of HBV viremia [43]. Not
surprisingly, then, the rate of HBeAg and HBsAg sero-
conversion has been shown to be highest in patients hav-
ing ALT ﬂares during treatment with pegylated
interferon [41,44].
HBsAg clearance, implying greater loss of covalently
closed circular (cccDNA), occurs in 3–5% of patients
within the ﬁrst year of follow-up in interferon-treated
patients and has been demonstrated to increase with
time in sustained virologic responders [45,46]. By con-
trast, HBsAg seroconversion is rare with nucleoside ana-
log therapy despite the greater antiviral potency of these
agents. These observations underscore the need for
future development of more eﬀective immunomodula-
tory therapy and provide a rationale for the use of inter-
feron in combination with one or more nucleoside
analogs.
6.2. Standard vs pegylated interferon
Standard interferon alfa-2b was ﬁrst made commer-
cially available as treatment for hepatitis B in 1992.
Phase III trials demonstrated that it was signiﬁcantly
more likely to result in HBeAg loss when compared to
untreated controls. Achieving this virologic endpoint
was associated with major improvement or normaliza-
tion in ALT and sustained loss of HBV DNA as mea-
sured by direct hybridization assay. In addition, early
studies indicated that HBsAg loss occurred in approxi-
mately one third of those losing HBeAg, and the rate
of HBsAg disappearance in virologic respondersincreased with prolonged follow-up [38,45,46]. Inter-
feron remained the only licensed treatment for hepatitis
B until lamivudine became available in 1998. Since then,
the use of nucleoside analog therapy has been preferred.
The reasons for this are multifactorial, but a driving
force has been the adverse events associated with the
use of interferon as well as the need for administration
by injection. In sharp contrast, nucleoside analogs are
orally delivered and generally free of adverse events.
There has been a resurrection of interest in the use of
interferon over the past several years because large mul-
ticenter and multinational studies have demonstrated an
enhanced antiviral potency for pegylated interferon alfa
and administration of ﬁrst generation nucleoside ana-
logs has been associated with the development of drug
resistance. When compared to standard interferon
alfa-2a administered in a dose of 4.5 million units three
times weekly, a 180 lg dose of pegylated interferon alfa-
2a resulted in a steeper decline in HBV DNA levels and
a higher rate of HBeAg seroconversion (33% vs 25%)
[39]. Less beneﬁt was observed with the 270 lg dose of
peginterferon, providing impetus for the incorporation
of 180 lg in phase III trials.
6.3. Pegylated interferon in combination with nucleoside
analog therapy for HBeAg-positive and HBeAg-negative
chronic hepatitis B
6.3.1. Review of clinical trial data
Three large phase III trials of pegylated interferon
have been published [40–42]. Two included only
HBeAg-positive patients, and the third enrolled only
HBeAg-negative subjects. Each incorporated a treat-
ment arm of pegylated interferon combined with lami-
vudine. In one study, pegylated interferon alfa-2b was
given in a dose of 100 lg weekly for 32 weeks followed
by 50 lg weekly until completion of 52 weeks of treat-
ment [40]. This treatment arm was compared to the
identical dose and duration of pegylated interferon
given simultaneously with 52 weeks of lamivudine.
Whereas there was a greater decline in HBV DNA in
the combined group (approximately 5 log vs 2 log)
as well as a higher rate of HBeAg loss (44% vs 29%)
at the end of treatment, these diﬀerences were not sus-
tained during a 26-week follow-up period. The reasons
for this discrepancy are unclear but the modiﬁcation in
dosage at the 32-week treatment interval could have
been a contributing element.
Of note, HBsAg loss occurred in 5% of the pegylated
interferon monotherapy group and 7% of the combined
therapy patients. One of the major ﬁndings of this study
was the relationship of HBeAg loss to HBV genotype.
Genotype A patients had the highest rate of HBeAg loss
(47%), followed by genotype B (44%), genotype C
(28%), and genotype D (25%). Further analyses of the
data demonstrated that the rate of HBeAg clearance
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induced ALT ﬂares [44] and the rate of HBsAg clearance
was closely linked to viral genotype (14%, 9%, 3%, and
2% for genotypes A, B, C and D, respectively) [47].
In the other 2 phase III trials, pegylated interferon alfa-
2a was given in a dose of 180 lg once weekly for 48 weeks
in HBeAg-positive and HBeAg-negative patients, respec-
tively [41,42]. In both studies, peginterferonmonotherapy
was compared to 48weeks of lamivudinemonotherapy or
the combination of lamivudine and peginterferon. As
with the pegylated interferon alfa-2b study above, end
of treatment decline in HBV DNA was more robust in
patients treated with the combination therapy (HBeAg-
positive: 7.2 log, 4.5 log, and 5.8 log, respectively,
for combination therapy, peginterferon alone, and lami-
vudine monotherapy; HBeAg-negative: 5.0 log, 4.1
log, and4.2 log, respectively). However, in both studies
combination therapy was not more eﬀective in achieving
sustained virologic response at the end of a 24-week fol-
low-up period. A potentially important ﬁnding was that
HBeAg seroconversion occurred more frequently in
patients with on treatment ALT ﬂares (deﬁned as ALT
levels 5  the baseline value) [45]. The rate of HBeAg in
this subgroup treated with peginterferon monotherapy
group was 43% vs 32% for the group as a whole, and the
magnitude of ALT ﬂares was seen to be closely correlated
with the rate of HBeAg seroconversion [48].
The phase III trials with peginterferon alfa-2a also
demonstrated that HBsAg seroconversion was limited
to patients who received peginterferon. While the rates
of HBsAg seroconversion were modest, occurring in
3% of all peginterferon-treated patients, this informa-
tion should be viewed in the context that 87% of the
HBeAg-positive and 61% of the HBeAg-negative sub-
jects were of Asian ethnicity which could have limited
the rate of HBsAg seroconversion. Furthermore, most
patients (60% of the HBeAg-positive and 67% of the
HBeAg-negative) had unfavorable genotypes (C and
D) for HBsAg clearance. Finally, multivariate analysis
conﬁrmed that baseline ALT, baseline HBV DNA
(6109 copies/mL), and low concentrations of pre-treat-
ment HBeAg were predictive of HBeAg seroconversion
[49]. In the HBeAg-negative study, predictors of sus-
tained virologic included baseline and end of treatment
HBV DNA, age and HBV genotype. When evaluated
at the one year post-treatment interval, patients with
genotype B or C had a signiﬁcantly greater chance for
combined biochemical and virologic response than did
patients with genotype D, and the latter group appeared
to do best with combined therapy [50].
6.3.2. Extended follow-up and durability of response
Prolonged follow-up has been achieved with a subset
of HBeAg-negative patients treated with peginterferon
alfa-2a in the phase III trial [51]. Only 230 of the original
peginterferon treated 354 patients were enrolled in thisextended follow-up study providing a potential selection
bias. Nonetheless, the data indicate that a substantial
proportion of patients who achieve a virological
response maintain this for at least 3 years. Due to the
high rate of relapse in HBeAg-negative chronic hepatitis
B, future studies need to include all patients on an
intent-to-treat basis in an extension of post-treatment
follow-up for at least 5 years.
6.3.3. Additional studies
Criticism has been directed to the phase III trials that
compared peginterferon alfa-2a to lamivudine mono-
therapy because the latter group of patients were only
treated for one year, which is not the way the drug is
used in clinical practice. Additionally, a number of smal-
ler studies have been published which give the sugges-
tion of enhanced therapeutic eﬃcacy when pegylated
interferon is used with lamivudine or adefovir as com-
pared to nucleoside analog or peginterferon mono-
therapy [52–55]. A small pilot study has been reported
in which adefovir was combined with pegylated inter-
feron alfa-2b, both administered for 48 weeks; not only
was the rate of HBeAg seroconversion higher (53%)
when compared to historical cohorts, but also the rate
of HBsAg seroconversion (15%) [55]. These data suggest
that the two drugs may work synergisitically to promote
greater elimination of cccDNA. Finally, the results from
a recent study from India suggest that therapeutic eﬃ-
cacy is enhanced when a nucleoside analog, in this case,
lamivudine, is used to lower HBV DNA levels before
commencing pegylated interferon [56].
6.3.4. Need for further studies
The current recommended duration of treatment with
pegylated interferon alfa-2a is 48 weeks. Because the fre-
quency of HBeAg seroconversion with 24 weeks of
pegylated alfa-2a interferon (33%) was not diﬀerent
from that achieved with a 48-week course (32%), an
appropriately powered trial comparing 24 vs 48 weeks
of therapy is warranted in HBeAg-positive disease
[39,41]. This is important because a shorter course of
peginterferon is likely to be better tolerated. By contrast,
prolongation of standard interferon therapy beyond 24
weeks has achieved a higher rate of sustained response
in HBeAg-negative hepatitis B [57,58]. The best viro-
logic endpoint that permits treatment discontinuation
with the lowest rate of relapse remains unclear. Early
studies that have incorporated serial measurement of
HBsAg concentration suggest this to be helpful [59,60].
Future studies should, therefore, monitor HBsAg con-
centration at ﬁxed time points during treatment which
may allow one to determine the length of therapy that
is needed in this diﬃcult to treat disorder.
The consistent demonstration of greater viral sup-
pression when peginterferon and lamivudine are taken
together as compared to either agent alone; the lower
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resistance to other nucleoside analogs) with combina-
tion therapy; and a surprisingly high rate of HBsAg
clearance when adefovir is used with peginterferon war-
rant further combination therapy studies. These studies
should include more potent nucleos(t)ides with a favor-
able resistance proﬁle and/or a high genetic barrier to
resistance such as tenofovir or entecavir. Because nucle-
oside analogs work slowly in promoting HBeAg sero-
conversion, the results of combination therapy should
be compared to the nucleoside analog alone given for
a suitably long period of time (for example, 2–4 years).
Also, it remains unresolved as to whether staggered
treatment rather than simultaneous therapy might be
more eﬀective, and this needs more careful assessment.
6.3.5. Importance of patient selection
All of the major practice guidelines have advocated
interferon as potential ﬁrst-line therapy for both
HBeAg-positive and HBeAg-negative hepatitis B. None-
theless, the use of interferon currently accounts for no
more than 10% of all prescriptions for hepatitis B treat-
ment in theUS andEurope, and the usage is apt to be even
less in Asia. This low usage pattern may be explained by
the unpleasant side eﬀects, lower antiviral potency, and
need for administration by injection. However, another
contributing element may be that the practice guidelines
do not speciﬁcally advocate its use as being preferred in
speciﬁc subsets of patients who are most likely to have a
sustained virologic response and HBsAg seroconversion.
Recently, advisements aboutwhen to use peginterferon as
ﬁrst-line therapy have been proposed [61,62]. For
HBeAg-positive patients, this includes selection of
patients with ALT at least twice the ULN and HBV
DNA levels less than or equal to 109 copies per mL at
baseline. Other factors that have not been speciﬁcally
addressed in analyses of the phase III clinical trial data
but seem prudent nonetheless include age less than 60
years of age and lack of cormorbid illnesses that might
decrease tolerability. The need for genotyping patients
who meet these criteria cannot be overemphasized since
genotype A and B patients have much higher rates of
HBsAg seroconversion as well as HBeAg seroconversion.
HBeAg-negative patients with genotypeD have the poor-
est response to interferon. The favorable results with a
combination of peginterferon and a nucleoside analog
in this most diﬃcult to treat subset of patients requires
further conﬁrmation [50].7. Nucleoside analogs
7.1. Mechanisms of action of nucleoside analogs
Nucleoside analogs inhibit the viral polymerase activ-
ity. Depending on the drug, this inhibitory activity canaﬀect the priming of reverse transcription, viral minus
strand DNA synthesis (i.e., RNA dependent DNA poly-
merase activity or reverse transcription), or plus strand
DNA synthesis (i.e., the DNA dependent DNA poly-
merase activity of the viral enzyme) [63]. None of these
drugs targets the RNAseH activity of the viral enzyme.
Lamivudine is mainly an inhibitor of the reverse trans-
criptase activity, while clevudine has been shown to
aﬀect both minus- and plus-strand DNA synthesis
[64,65]. Adefovir and tenofovir are active on the priming
of reverse transcription as well as on elongation of viral
minus strand DNA [66,67]. Entecavir inhibits both
minus and plus strand DNA synthesis [68]. Telbivudine
is also supposed to inhibit all three enzymatic activities
[69]. It is unknown if antiviral potency is aﬀected by
more than one site of inhibition. Results of in vitro stud-
ies suggest an additive antiviral eﬀect for some combina-
tions of nucleoside analogs [70,71], but this has not been
demonstrated by clinical trials in which the antiviral eﬃ-
cacy was driven by the most potent drug in the combina-
tion [72,73].
All nucleoside analogs are competitive inhibitors of the
viral polymerase as they compete with the incorporation
of the natural endogenous intracellular nucleotides in
nascent viral DNA.Furthermore, once incorporated they
can also terminate DNA synthesis by preventing the
incorporation of the next nucleotide in the viral DNA
strand. The eﬀect of nucleoside analogs on viral polymer-
ase activity results in a decreased production of infectious
viral particles and, therefore, limits the spread of virus to
uninfected hepatocytes.
7.2. Eﬀects of antiviral therapy on intrahepatic cccDNA
One of the major questions concerning antiviral ther-
apy of chronic hepatitis B is whether treatment might be
able to deplete the pool of intrahepatic cccDNA to levels
below which the adaptive and innate anti-HBV immune
responses might control the infection, and eventually
clear cccDNA. Experimental data obtained in tissue cul-
ture systems and in animal models of hepadnavirus infec-
tion have shown that none of the currently available
nucleoside is able to prevent the de novo formation of
cccDNA in infected hepatocytes [74,75]. This implies that
residual viremia during antiviral therapy may lead to the
infection of newhepatocytes. Furthermore, in chronically
infected cells, the eﬀect of nucleoside analog administra-
tion does not completely block the recycling of nucleo-
capsids towards the nucleus. Because of the long half
life of cccDNA and that of infected hepatocytes, the
decrease in cccDNA levels during nucleoside administra-
tion has been shown to be primarily associated with hepa-
tocyte turn-over [76–78]. What seems critical is that,
cccDNA is lost during cell division and by drug-induced
inhibition of viral replication not transmitted to progeny
cells leading to a dilution of infected cells.
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quantiﬁcation of cccDNA in the liver of patients under-
going antiviral therapy. These relatively short-term stud-
ies have demonstrated that cccDNA persists in the liver
of the majority of the patients during treatment [79,80].
Curiously, it has been shown that administration of ade-
fovir, one of the less potent nucleoside analogs, may
decrease the levels of intrahepatic cccDNA [81]. Fur-
thermore, the combination of pegylated interferon with
adefovir has been reported to enhance the clearance of
cccDNA [55]. Studies with appropriate treatment con-
trol arms are needed, however, to conﬁrm these observa-
tions. It is very important that established and future
therapies be properly analyzed for their eﬀect on the
clearance of cccDNA because a progressive decrease of
this genomic template, whether induced by nucleoside
analogs and/or by interferon, can lead to HBsAg clear-
ance. Several small scale studies have shown that the
decline of intrahepatic cccDNA paralleled that of serum
HBsAg [55,81,82].
7.3. Licensed nucleoside analogs
7.3.1. Lamivudine
This nucleoside analog is a potent inhibitor of the
viral polymerase activity, has an excellent safety pro-
ﬁle, and is the least expensive of the licensed nucleo-
side analogs. Despite these features, it is no longer
recommended as ﬁrst-line therapy because it induces
a high rate of drug resistance, especially during
long-term administration [83,84]. However, several
studies have shown its potential usefulness when used
short-term. It was shown that lamivudine administra-
tion during the third trimester of pregnancy in highly
viremic mothers may decrease viral load and enhance
the prophylactic eﬃcacy of HBV vaccination in neo-
nates [85]. Another indication might be the treatment
of acute severe hepatitis, as some studies have demon-
strated an improved clinical outcome in patients who
received lamivudine [86]. Moreover, several studies
have shown lamivudine to be eﬀective in the preven-
tion of HBV reactivation and ALT ﬂares in chronic
carriers who receive immunosuppressive therapy or
chemotherapy [87,88]. In fact, the eﬃcacy of nucleo-
side analogs such as lamivudine in this setting has
led to a suggestion that all potential recipients of che-
motherapy be screened for HBsAg and/or anti-HBc
before chemotherapy.
It is also noteworthy that approximately 20% of
patients maintain viral suppression during 5 years of
lamivudine treatment. Although several factors have
been identiﬁed as predictors of lamivudine resistance,
i.e., high viral load, high HAI, and high BMI [83,89],
it is still diﬃcult to predict before treatment initiation
which patients will maintain viral suppression during
lamivudine therapy.7.3.2. Adefovir dipivoxil
Adefovir dipivoxil has an interesting antiviral activity
proﬁle. It is as active on wild-type virus as on lamivu-
dine-resistant mutants, both in vitro in tissue culture
models and in vivo in patients. Therefore, it was
approved as a ﬁrst-line therapy, but also as a rescue
therapy for patients with lamivudine resistance [90,91].
Its clinical interest is limited by its moderate antiviral
potency as compared to other nucleoside analogs. For
instance, it was shown that approximately 25% of
patients have a viral load decline lower than 2.2
log10 copies/mL after one year of administration [92–
94]. This is particularly true for HBeAg-positive patients
with high viral load. On the other hand, most HBeAg-
negative patients may beneﬁt from long-term adefovir
administration because of lower baseline viremia levels,
and a relatively low rate of selection of drug-resistant
mutants. Adefovir-resistant mutants are detected by
population sequencing in approximately 29% of patients
after 5 years of therapy [95]. Interestingly, the adefovir-
resistant strains are usually susceptible to lamivudine
and vice versa.
Currently, adefovir dipivoxil should be used primar-
ily for the treatment of HBeAg-negative chronic hepati-
tis. Another indication is the rescue of lamivudine
resistance with the best results occurring when initiated
as soon as viremia levels start to rise [96]. Several studies
have shown that the addition of adefovir to lamivudine,
rather than switchover to adefovir monotherapy, results
in a lower rate of adefovir resistance [97]. It might be
replaced in the near future by tenofovir which shows a
similar antiviral activity spectrum but a much better
antiviral potency.
7.3.3. Entecavir
This nucleoside analog is a very potent anti-HBV
agent which induces dramatic decline in viral load in
both HBeAg-positive and -negative patients [98,99].
Despite this strong antiviral potency, the rate of HBeAg
seroconversion is relatively low and comparable to that
observed with other nucleoside analogues. In naı¨ve
patients, the rate of emergence of entecavir-resistant
strains seems to be very low even after four years of
therapy [100]. By contrast, entecavir administration in
patients with lamivudine resistance give rise to enteca-
vir-resistant mutants in more than 35% of patients after
4 years of therapy [101,102]. This is due to a particular
mode of selection of entecavir strains which follows a
two-step process with the selection of primary resistance
mutations [at position rt204 which are also resistant to
lamivudine], followed by the addition of secondary resis-
tance mutations on the same viral genomes [103,104].
Once these secondary substitutions occur, high level
resistance to entecavir occurs.
While entecavir was believed not to be active against
HIV reverse transcriptase, recent reports have shown
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patients may select for HIV mutants that are resistant
to lamivudine [105]. The best indication for entecavir
therapy is represented by HBeAg-positive or -negative,
nucleoside naı¨ve, patients. Entecavir should be used cau-
tiously in patients with lamivudine resistance and those
who are co-infected with HIV.
7.3.4. Telbivudine
This is a nucleoside analog with strong antiviral
potency, found to be comparable to that of entecavir
in phase III clinical trials in both HBeAg-positive and
-negative patients [72,106,107]. In HBeAg-positive
patients, the rate of HBe seroconversion at 52 and 104
weeks is comparable to that of entecavir and lamivu-
dine. Unfortunately, its administration is associated
with a resistance rate of approximately 10% per year.
Phase III clinical studies have helped to identify on-
treatment predictive factors for virologic response and
drug resistance, with primary importance given to per-
sisting viremia at 24 weeks of treatment. Telbivudine
mainly selects for rtM204I mutation which is also resis-
tant to lamivudine and entecavir, but sensitive to adefo-
vir and tenofovir.
While the drug can be used for nucleoside naı¨ve
patients, the low rates of resistance with tenofovir and
entecavir have led to a more restricted pattern of use.
Importantly, it can be used against adefovir-resistant
mutants. Telbivudine is priced higher than lamivudine,
but is considerably less expensive than adefovir, tenofo-
vir, and entecavir. Correspondingly, it may ﬁnd more
use when economic considerations are of major impor-
tance. Its use in combination regimen should also be
evaluated in clinical trials.
7.3.5. Tenofovir
Tenofovir belongs to the same family of nucleotide
analogs as adefovir. It exhibits a potent inhibitory
activity against the wild-type and drug-resistant
mutants (i.e., lamivudine and entecavir-resistant
strains) [108,109]. Clinical experience has been mainly
in HIV–HBV co-infected patients as tenofovir is also
active against the HIV reverse transcriptase [110–
113]. In this setting, it has been shown that tenofovir
can control HBV replication in the majority of
patients and can rescue HBV lamivudine failure.
Moreover, clinical studies have demonstrated it to be
eﬀective when there is primary non-response to adefo-
vir in non-HIV infected patients. In HIV co-infected
patients, it has been mainly prescribed as an add-on
therapy with lamivudine, and more recently as a com-
bination with emtricitabine, another nucleoside analog
with an antiviral activity proﬁle that is similar to lam-
ivudine for both HBV and HIV. This may be the rea-
son why until now, there has been no deﬁnite
observation of HBV resistance to tenofovir. It willbe interesting to see whether this holds true when ten-
ofovir is prescribed as monotherapy.
Recent results of ongoing phase III studies in chronic
hepatitis B patients, negative for HIV, have shown that
tenofovir has a better antiviral eﬃcacy compared to that
of adefovir [114,115]. Approximately 75% and 90% of
HBeAg-positive and -negative patients, respectively,
achieved undetectable HBV DNA by quantitative
PCR after one year of therapy. In HBeAg-positive
patients, the rate of HBe seroconversion was the same
as that observed with other nucleoside analogs. Fol-
low-up of patients undergoing long-term tenofovir
administration is ongoing.
Because of its spectrum of antiviral activity, it can be
recommended for use in both naı¨ve patients and those
with ﬁrst-line treatment failure. Indeed, there is in vitro
and in vivo evidence suggesting that it is active against
lamivudine, entecavir, telbivudine and even adefovir-
resistant mutants. In this setting, an add-on strategy
or a switch to a combination of tenofovir plus emtricit-
abine might be recommended; clinical studies are war-
ranted in this setting.8. Failed response and viral resistance to nucleoside
analogs
8.1. Deﬁnitions
8.1.1. Response
Virologic response is deﬁned by the decline in HBV
DNA below 100,000 or 10,000 copies/mL, the biochem-
ical response by the normalization of ALT levels, and
the histological response by the improvement in the
inﬂammatory activity or ﬁbrosis indices [7]. Most stud-
ies have used a 2 point or greater change in necroinﬂam-
matory score without any negative change in ﬁbrosis as
a deﬁning element for histologic response. The com-
bined response is deﬁned by the improvement in ALT
levels and decrease in viral load while the complete
response is characterized by the combination of the
decrease in viral load, the normalization of ALT levels,
the occurrence of an HBe or HBs seroconversion, and
an improvement in the histologic appearance.
The treatment response is also deﬁned depending on
the timing during therapy [116]. The initial response is
characterized by a decrease in viral load, at week 12 of
therapy, by at least one log10 copies/mL compared to
the baseline value. The maintained response is deﬁned
by a continuing low viral load during therapy. Depend-
ing on the use of nucleoside analog or interferon, there is
no universally agreed upon threshold to deﬁne the main-
tained response. Usually, a decrease of viral load below
10,000 copies/mL is associated with an improvement of
liver histology. However, with nucleoside analogs, the
lower the viral load, the less the risk of developing drug
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the response observed at the end of therapy, if it was
decided to stop treatment. A relapse is deﬁned by the
increase in viral load after treatment cessation. The sus-
tained response is conventionally deﬁned by the mainte-
nance of the response 6 months after drug withdrawal.
A durable response has been used to suggest prolonged
viral suppression long after the end of therapy.
8.1.2. Primary non-response
The failure to achieve a one log10 copies/mL decline
in viral load after 12 weeks of therapy is considered as
a primary non-response. It indicates that either there
is a compliance issue or that the medication does
not exhibit its antiviral activity in a given patient;
one large study demonstrated that a suboptimal
response may be due to a host pharmacological eﬀect
or to patient compliance but not a reduced susceptibil-
ity to adefovir as measured in vitro [94]. When a sub-
optimal response is identiﬁed, antiviral treatment
should be modiﬁed. Many experts would choose to
switch to a more potent nucleoside analog at this
interval. The week 12 time point is therefore impor-
tant to determine the antiviral activity of the treat-
ment regimen. Partial response after 6–12 months
depending on the drugs and the kinetics of viral load
decline should lead to treatment adaptation.
8.1.3. Partial response
A partial response corresponds to the failure to
achieve a viral load decline to a threshold that translates
to an improvement in liver histology and/or to a mini-
mum risk of resistance. When considering liver histology
as an endpoint, antiviral therapy should lead to a
decrease in HBV DNA levels to below 100,000 copies/
mL. Due to lower baseline HBV DNA levels, some
experts would suggest a lower level is necessary for his-
tological improvement in HBeAg-negative chronic hep-
atitis B (i.e., 10,000 copies/mL). The risk of drug
resistance, however, is associated with much lower viral
loads than 100,000 copies/mL.
The antiviral response at week 24 of therapy was also
found to be a predictor of resistance in patients treated
with telbivudine or lamivudine in the Globe trial [117].
Higher rate of resistance at 2 years was observed when
week 24 viral load was >1000 copies/mL compared to
patients with a lower viral load at the same time point,
whatever their initial HBeAg status. The rate of HBeAg
seroconversion at year 2 was 46% in patients with unde-
tectable viral DNA at week 24 vs 6% for those having
viral DNA levels higher than 6 log10 copies/mL at week
24. The rate of resistance to telbivudine at year 2 was 4%
in HBeAg-positive and 2% in HBeAg-negative patients
with undetectable HBV DNA levels at week 24, vs
30% and 60% for patients with viremia levels higher
than 10,000 copies/mL at week 24.Adefovir dipivoxil was shown to suppress viremia
levels with a slower eﬀect by comparison with other
nucleoside analogs, i.e., lamivudine, entecavir or telbivu-
dine. Therefore, the week 48 time point may be used for
predicting resistance to ADV therapy [95]. Interestingly,
it was demonstrated in HBe-negative patients treated
with adefovir dipivoxil for 192 weeks, that patients with
HBV DNA levels 1000 copies/mL after 48 weeks of
therapy had a higher risk of developing adefovir resis-
tance at week 192. 17/35 patients (49%) developed
ADV-resistant mutants, as compared to 6% (5/89) of
patients with a viral load <1000 copies/mL at week 48.
From these diﬀerent studies, the current deﬁnition of
partial response is the failure to achieve viral suppres-
sion below 1000 copies/mL after 6–12 months of ther-
apy. This should lead to treatment adaptation to
maximize viral suppression and minimize the subsequent
risk of resistance [118]. The timing of treatment adapta-
tion depends on the drug used and on the kinetics of
viral load decay, especially in patients starting from very
high viral load who may need additional weeks of ther-
apy to reach the threshold of 1000 copies/mL.
8.1.4. Virologic breakthrough
Virologic breakthrough is deﬁned by an increase of at
least one log10 copies/mL compared to the lower value
during treatment, conﬁrmed by a second test, in a treat-
ment compliant patient. It is usually associated with the
presence of resistance mutations and follows genotypic
resistance (detection of resistance mutations)
[116,119,120]. The conﬁrmation by a second HBV
DNA test is not necessary when patients present also
with ALT elevation.
In the absence of treatment adaptation, the rise in
viremia levels may be followed in the following weeks
or months by an increase in ALT levels (biochemical
breakthrough) and subsequently progression of liver dis-
ease (clinical breakthrough).
8.2. Treatment adaptation
8.2.1. Cross-resistance
Cross-resistance refers to the situation in which a
decreased susceptibility to more than one antiviral drug
is conferred by the same amino acid substitution or
combination of amino acid substitutions. Results of
in vitro cross-resistance data are summarized in Table 3.
Results of in vitro cross-resistance testing have shown
that lamivudine-resistant mutants (rtM204V or rtM204I
mutants) are not sensitive to other L-pyrimidine analogs
such as emtricitabine, clevudine, and telbivudine while
they remain susceptible to purine analogs such as adefo-
vir and tenofovir [64,66,121,122]; these mutants also
have an intermediate susceptibility to entecavir
[103,104]. In vitro studies demonstrated that rtN236T
adefovir-resistant mutant is susceptible to lamivudine,
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rtA181V mutant has a reduced susceptibility to lamivu-
dine [123–125]. Although some level of cross-resistance
has been observed in vitro, rtN236T adefovir-resistant
strains remain sensitive to tenofovir in vivo at least ini-
tially, most likely because of the greater exposure to
active drug. The A181V mutant-resistant to adefovir
was shown to be as sensitive to tenofovir in vitro as
wild-type HBV [126]. Further trials of longer duration
are needed to see if tenofovir may maintain a sustained
response in patients with adefovir-resistant strains. Two
mutants are subject to a controversy, the rtI233V muta-
tion was shown to confer primary to resistance to adefo-
vir in one study but not in another one [127,128]; the
rtA194T has been associated with the emergence of
HBV resistance to tenofovir in one study but this was
not conﬁrmed by another [66,129].
Current data suggest that the development of enteca-
vir resistance follows a ‘‘two hits” model with the ﬁrst
selection of primary resistance mutations at position
rt204, followed by the addition of secondary resistance
mutations (at position rt184, rt202, or rt250) conferring
higher resistance to entecavir [103,104]. This may
explain why the development of entecavir resistance is
more rapid in patients with lamivudine failure who
already have selected the primary resistance mutations,
by comparison with the nucleoside naı¨ve patients in
whom the whole process of selection of primary and sec-
ondary mutations needs to take place. Although strains
harboring classic lamivudine resistance mutations exhi-
bit an intermediate susceptibility to entecavir, they
remain sensitive initially to entecavir in vivo, when this
latter is administered at a higher dose (1.0 mg daily).
If additional secondary mutations occur, resistance to
entecavir is observed and is followed by viral break-
through. This suggests that entecavir may not be consid-
ered as an optimal treatment for patients infected with
lamivudine-resistant HBV, but a good treatment option
in nucleoside naı¨ve patients. If entecavir has to be pre-
scribed in patients with lamivudine failure, lamivudine
should be discontinued, and entecavir prescribed at dou-
ble dose (1 mg daily).Table 3
Cross-resistance proﬁle of nucleoside analogs for hepatitis B as measured in vi
Lamivudine Telbivudin
Wild-type S S
M204l R R
L180M +M204V R R
A181T/V I S
N236T S S
I169T + V173L +M250Vb R R
T184G + S202I/Gb R R
R, resistant; S, susceptible; I, decreased in vitro activity.
a Results were obtained in vitro in tissue culture experiments using trans
diﬀerent drug resistant mutants as described in references: [66,102–104,122,1
b These mutations are observed on a genetic background of mutations atTelbivudine is ineﬀective in vitro against the rtM204I
mutant as well as the rtL180M +M204V mutant, but
remains active against the rtM204V single mutant. This
may explain why the single rtM204I mutant has been the
only resistant mutant detected during the phase III trials
of telbivudine.
8.2.2. Problems with sequential monotherapy: multi-drug
resistance
Based on clinical experience, the knowledge of cross-
resistance, and viral quasi-species evolution during ther-
apy, it was clearly shown that sequential therapy may
expose the patients to the risk of selection of multi-drug
resistant strains. One example is the use of sequential
treatment with cross-resistance drugs like lamivudine
followed by entecavir [104,130], and another being the
development of dual resistance to both lamivudine and
adefovir [125,131]. It was shown by clonal analyses that
multi-drug resistance may occur by the sequential addi-
tion of resistance mutations on the same viral genome
leading to resistance to both drugs. Results of pheno-
typic analysis of the mutants during the selection pro-
cess demonstrated that the cumulative addition of
these mutations conferred full resistance to both drugs.
Another situation is the use of an add-on strategy
with drugs having a complementary cross-resistance
proﬁle which may lead to the selection of multi-drug
resistant strains if the add-on strategy does not induce
a complete viral suppression, especially if there is a large
replication space available for the mutants to spread.
This was demonstrated by the longitudinal clonal anal-
ysis and phenotypic analysis of the main variants in a
patient who selected a multi-drug resistant strain, after
liver transplantation, harboring mutations in the over-
lapping polymerase and surface that conferred resis-
tance to both lamivudine and adefovir as well as a
decreased recognition by anti-HBs antibodies [125].
Because of the risk of development of multi-drug
resistance which may not be rescued by currently avail-
able drugs, treatment decision and the choice of ﬁrst-line
treatment should be made with caution. Furthermore, in
speciﬁc patient populations with a high risk of resistancetroa
e Entecavir Adefovir Tenofovir
S S S
R S S
I S S
S R S
S R I
R S S
R S S
ient transfection experiments or cell lines permanently expressing the
25,126,131,139].
position rtM204.
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tolerated, de novo combination therapy should be con-
sidered to minimize the risk of resistance development.
8.2.3. Add-on therapy with drugs lacking cross-resistance
In the past, salvage therapy was proposed to patients
with lamivudine resistance and clinical breakthrough
(high viral load and ALT elevation). There was a debate
on whether adefovir dipivoxil switch or add-on to ongo-
ing lamivudine was the best strategy. The knowledge of
cross-resistance data and the results of long-term studies
advocate for an add-on therapy at an early stage, i.e.,
viral breakthrough, to control rapidly viral replication
and prevent clinical deterioration. Several studies have
shown that switching from lamivudine to adefovir
monotherapy was associated with a high incidence of
adefovir resistance. A large multicenter Italian cohort
study showed that rescue therapy with the addition of
adefovir after development of virological breakthrough
in HBeAg-negative patients treated with lamivudine
led to viral suppression for three years in most patients
[132]. None of the patients receiving the add-on strategy
developed genotypic resistance to adefovir by contrast
to those who received adefovir monotherapy. Another
Italian study compared two groups of patients with
known resistance to lamivudine: in one group, adefovir
was added at the time of clinical breakthrough with high
viremia levels, while in the other group, adefovir was
introduced earlier, at the time of viral breakthrough
[96]. The results clearly showed that treatment eﬃcacy
was improved when adefovir was started earlier, at the
time of virologic escape.
8.3. Importance of virologic monitoring
The objective of viral load levels measurement is two-
fold, ﬁrstly to monitor magnitude of viral load suppres-
sion, and secondly to detect viral breakthrough as early
as possible [116,119,133].* Choice based on cross-resistance data
Partial virologic response
Nucleoside
A
sw
em
Monitor
at 12-24 weeks
Early non-response
ev
Switch to more
potent agent*
Fig. 1. Secondary treatment preferenceEarly during therapy, at week 12, viral load assess-
ment allows to conﬁrm the initial antiviral response. A
primary treatment failure is an indication to change
treatment regimen at an early stage. The next monitor-
ing time point should be at week 24 of therapy. This
measurement is considered essential in the management
of both HBeAg-positive and HBeAg-negative patients,
because it was found to be the main predictor of subse-
quent treatment eﬃcacy in terms of HBeAg seroconver-
sion in HBeAg-positive patients, and of subsequent
resistance [118,134].
Altogether a precise monitoring of viral load during
antiviral therapy allows the diagnoses of primary treat-
ment failure, insuﬃcient viral suppression predicting a
high likelihood of drug-resistance development, or viro-
logic breakthrough. In all these situations, an early
intervention is mandatory to adjust antiviral therapy
and control viral replication to prevent clinical deterio-
ration (Fig. 1).
The use of genotypic assays to deﬁne the resistance
pattern and adapt antiviral treatment accordingly is crit-
ically important (Table 3). Indeed, since more and more
patients have received several courses of drug therapy,
the pattern of resistance mutations is becoming more
and more complex. Its knowledge is becoming impor-
tant to make informed treatment decisions. There are
still many issues to be addressed. One is the fact that
the currently available assays can detect only the major
variants in the viral quasi-species, and it will be even
more diﬃcult to detect mutants that are archived in
intrahepatic cccDNA and will emerge only in the pres-
ence of a speciﬁc antiviral pressure [125,135]. Another
issue is the cost of the assays and the reimbursement pol-
icy from country to country. In any case, genotypic
assays for the detection of drug-resistant mutants would
be recommended in patients who experience a virologic
breakthrough. Currently, we still do not know if these
assays are sensitive enough to detect resistant mutants
in case of partial virologic response. Also, the commer-Virologic breakthrough
analog treatment
dd a more potent agent* or 
itch to a combination of 
tricitabine/tenofovir*
Monitor
ery 12 weeks
s based on virologic monitoring.
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gonucleotide probes only for the most commonly
deﬁned mutations.
8.4. Combination nucleoside analog therapy
With the availability of new antivirals, the concept of
combination therapy for chronic hepatitis B has been
debated over the past several years. Despite the lessons
drawn from the antiretroviral therapy of HIV infection,
the situation is clearly diﬀerent. Indeed, the antiretrovi-
ral drugs belong to several diﬀerent classes of com-
pounds which target diﬀerent steps of the viral life
cycle. It was therefore easier to demonstrate in relatively
short-term clinical trials that the combination of antiret-
rovirals can achieve an additive eﬀect on viral load sup-
pression. Furthermore, HIV drug resistance emerges
rapidly during monotherapy. The beneﬁcial eﬀect of
combinations was, therefore, assessed in short-term tri-
als showing the added value of combination in terms
of viral load decline, prevention of drug resistance and
decrease in mortality rate [136].
By contrast, in the setting of chronic hepatitis B,
antivirals belong to the same class of nucleos(t)ide ana-
logs and target the viral polymerase and no other key
step of the HBV life cycle [63]. This might be the reason
why the combination of nucleoside analogs did notLow viremia (< 7-8 log copies/mL)
Intermediate/
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Fig. 2. Suggested treatment preferences: ﬁrst-line antiviral therapy.show any additive eﬀect in terms of viremia decline com-
pared to the most potent antiviral drug in the combina-
tion [72,73,137].
The issue of prevention of drug resistance by combi-
nation therapy is critical. Several drugs with diﬀerent
cross-resistance proﬁles are now approved. Clinical
experience has shown that the combination of nucleo-
side analogs with complementary cross-resistance proﬁle
is an eﬀective strategy to manage resistance [96]. The
new generation of inhibitors has also an improved resis-
tance proﬁle with very low rates of resistance in nucleo-
side naı¨ve patients during the ﬁrst ﬁve years of therapy.
The beneﬁt of combination therapy will therefore be dif-
ﬁcult to demonstrate in short-term trials.
It will, therefore, become an urgent priority in the
future to identify the patients who have the highest risk
of resistance (for example, long standing infection and
high viremia levels associated with more complex viral
populations prior to therapy, together with high ALT
levels which are associated with a more rapid hepatocyte
turnover that in turn generates a wider replication
space) [83,138,78]. An equally important group for pre-
ferred use of combination therapy exists in those
patients who can least aﬀord to develop antiviral drug
resistance from a clinical perspective (for example,
patients with liver cirrhosis and/or with HBV recurrence
after liver transplantation) (Fig. 1). Strategy trials com-Decompensated liver disease/
Transplantation/immune suppression
Pregnancy/
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case of partial response should be designed and evalu-
ated as soon as possible in these patient groups.9. Conclusions
Major breakthroughs in the treatment of chronic
hepatitis B have occurred in the last ten years. However,
much remains to be done. Strict adherence to the prac-
tice guidelines of the major liver associations can result
in missed opportunities for treatment, particularly when
using the suggested ALT thresholds. It can be argued
that the use of the current ALT threshold of twice the
upper limit of normal is an indictment of the inadequacy
of our current drug therapy. Peginterferon is more
potent than standard interferon, yet its use has been rel-
egated to a few patients only. This is unfortunate since
genotype A and B patients respond well and may lose
HBsAg. The loss of hepatitis B surface antigen in
response to peginterferon therapy, while infrequent in
the short term, increases with time; this eﬀect provides
proof for a higher level of viral clearance when com-
pared to nucleoside analogs. In the authors’ opinion,
more study needs to be given to a combination of pegin-
terferon and newer nucleosides with lower rates of viral
resistance and greater antiviral potency.
While the newer nucleoside analog agents have been
associated with much lower rates of drug resistance, this
continues to be a concern when monotherapy is used.
Part of this concern rests on the knowledge that drug
resistant mutants exist in nature and if there is not a
rapid and robust decline in HBV DNA, this may allow
for selection pressures for drug-resistant virus. Thus,
drugs with high antiviral potency are preferable over
those in which responses occur more slowly, and
patients need to be monitored early on and at regular
intervals to document that an appropriate antiviral
response is occurring. The common practice of using
sequential monotherapy raises concerns because multi-
drug resistant virus has been detected in both non-
immunosuppressed and immunosuppressed patients.
For this reason, most experts recommend adding on
therapy rather than switchover to a nucleoside lacking
evidence for cross-resistance (Fig. 1). There is still a
debate by clinical virologists and infectious disease spe-
cialists as to whether we ought to be following the model
with HIV of multi-drug therapy as a ﬁrst-line approach.
It is quite clear that this would greatly diminish the rate
of drug resistance, but this approach has considerable
cost implications and uncertain eﬀects on enhancing
antiviral potency. The real question may be in which
subpopulation of patients is combination therapy pref-
erential? For example, it would be useful to have appro-
priately designed studies in which patients judged to be
at highest risk for resistance, for example, cirrhoticpatients with high level viremia, in whom the complexity
of the viral quasi-species may predispose to the presence
of pre-existing resistant mutants in higher proportion in
the viral population, are treated with either combination
therapy or monotherapy with a high potency, low resis-
tance nucleoside.
In summary, the number of therapeutic choices fac-
ing the clinician has expanded greatly, but hepatitis B
is not a disorder best treated with a ‘‘one-size ﬁts all
strategy.” The best choice is often based on the knowl-
edge of host variables as well as virologic and clinical
features of disease (Fig. 2). As with many other things
in medicine, careful selection and individualized treat-
ment decisions may ultimately prove best.References
[1] Lavanchy D. Hepatitis B virus epidemiology, disease burden,
treatment, and current and emerging prevention and control
measures. J Viral Hepat 2004;11:97–107.
[2] WHO. Hepatitis B vaccines. Wkly Epidemiol Rec 2004;79:255–
263.
[3] Fattovich G. Natural history of hepatitis B. J Hepatol
2003;39:S50–S58.
[4] Perrillo RP. Acute ﬂares in chronic hepatitis B: the natural and
unnatural history of an immunologically mediated liver disease.
Gastroenterology 2001;120:1009–1022.
[5] Rehermann B. Immune responses in hepatitis B virus infection.
Semin Liver Dis 2003;23:21–38.
[6] Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiﬀ ER, Schalm
SW, et al. Predictors of HBeAg loss after lamivudine treatment
for chronic hepatitis B. Hepatology 2002;36:186–194.
[7] Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology
2007;45:507–539.
[8] de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A,
McIntyre N, et al. EASL International Consensus Conference on
Hepatitis B. 13–14 September, 2002 Geneva, Switzerland.
Consensus statement (long version). J Hepatol 2003;39:S3–S25.
[9] Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan
G, et al. Asian-Paciﬁc consensus statement on the management
of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472–489.
[10] Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA
levels during diﬀerent stages of chronic hepatitis B infection.
Hepatology 2002;36:1408–1415.
[11] Manesis EK, Papatheodoridis GV, Sevastianos V, Cholongitas
E, Papaioannou C, Hadziyannis SJ. Signiﬁcance of hepatitis B
viremia levels determined by a quantitative polymerase chain
reaction assay in patients with hepatitis B e antigen-negative
chronic hepatitis B virus infection. Am J Gastroenterol
2003;98:2261–2267.
[12] Papatheodoridis G, Manesis E, Manolakopoulos S, Goulis J,
Chrysanthos N, Bilalis A, et al. HBeAg-negative chronic
hepatitis B (CHBe) in chronic HBV patients with serum
HBV-DNA levels below 2000 IU/mL. J Hepatol 2007;46:S183.
[13] Bonino F, Brunetto MR. Chronic hepatitis B e antigen (HBeAg)
negative, anti-HBe positive hepatitis B: an overview. J Hepatol
2003;39:S160–S163.
[14] Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J,
Pelissier E, et al. Factors associated with serum alanine trans-
aminase activity in healthy subjects: consequences for the
deﬁnition of normal values, for selection of blood donors, and
for patients with chronic hepatitis C. MULTIVIRC Group.
Hepatology 1998;27:1213–1219.
S16 F. Zoulim, R. Perrillo / Journal of Hepatology 48 (2008) S2–S19[15] Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I.
Normal serum aminotransferase concentration and risk of
mortality from liver diseases: prospective cohort study. BMJ
2004;328:983.
[16] Yang L, Xu K, Zhao Y, Wu Z, Chen T, Qin Z, et al. Clinical
signiﬁcance of liver biopsy in chronic hepatitis B patients with
persistently normal transaminase. Chin J Dig Dis
2002;3:150–153.
[17] Mohamadnejad M, Montazeri G, Fazlollahi A, Zamani F,
Nasiri J, Nobakht H, et al. Noninvasive markers of liver ﬁbrosis
and inﬂammation in chronic hepatitis B-virus related liver
disease. Am J Gastroenterol 2006;101:2537–2545.
[18] Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan
AO, et al. Prognostic determinants for chronic hepatitis B in
Asians: therapeutic implications. Gut 2005;54:1610–1614.
[19] Lai CL, Yuen MF. The natural history and treatment of chronic
hepatitis B: a critical evaluation of standard treatment criteria
and end points. Ann Intern Med 2007;147:58–61.
[20] Keeﬀe EB, Dieterich DT, Han SH, Jacobson IM, Martin P,
Schiﬀ ER, et al. A treatment algorithm for the management of
chronic hepatitis B virus infection in the United States: an
update. Clin Gastroenterol Hepatol 2006;4:936–962.
[21] Perrillo RP, Gish RG, Peters M, Keeﬀe EB, Alberti A, Buti M,
et al. Chronic hepatitis B: a critical appraisal of current
approaches to therapy. Clin Gastroenterol Hepatol
2006;4:233–248.
[22] Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al.
Hepatitis B e antigen and the risk of hepatocellular carcinoma. N
Engl J Med 2002;347:168–174.
[23] Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting
cirrhosis risk based on the level of circulating hepatitis B viral
load. Gastroenterology 2006;130:678–686.
[24] Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al.
Hepatitis B virus genotype and DNA level and hepatocellular
carcinoma: a prospective study in men. J Natl Cancer Inst
2005;97:265–272.
[25] Chen G, Shen FM, Iloeje UH, Evans A. Viral load as a predictor
of liver disease in chronic hepatitis B infection. Hepatology
2004;40:594A.
[26] Iloeje U, Yang H, Su J, Jen C, Kuo E, You S, et al.
Viral load is a strong predictor of hepatocellular carcinoma
risk in people chronically infected with hepatitis B virus
and normal serum alanine aminotransferase level. J Hepatol
2005;42:179.
[27] Evans A, Fabre R, Chen G, Pasternak L, Iloeje U, London W.
Hepatitis B viral load is associated with the development of
hepatocellular carcinoma. Hepatology 2004;40:602A.
[28] Chen G, Lin W, Shen F, Iloeje U, London W, Evans A. Viral
load as a predictor of mortality from hepatocellular carcinoma
and chronic liver disease in chronic hepatitis B infection. J
Hepatol 2005;42:173.
[29] Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of
hepatocellular carcinoma across a biological gradient of serum
hepatitis B virus DNA level. JAMA 2006;295:65–73.
[30] Perrillo R. Hepatitis B virus replication  time equals trouble.
Gastroenterology 2006;130:989–991.
[31] Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al.
Lamivudine for patients with chronic hepatitis B and advanced
liver disease. N Engl J Med 2004;351:1521–1531.
[32] Sherman M. Predicting survival in hepatitis B. Gut
2005;54:1521–1523.
[33] Hui CK, Leung N, Yuen ST, Zhang HY, Leung KW, Lu L, et al.
Natural history and disease progression in Chinese chronic
hepatitis B patients in immune-tolerant phase. Hepatology
2007;46:395–401.
[34] Lin CL, Liao LY, Liu CJ, Yu MW, Chen PJ, Lai MY, et al.
Hepatitis B viral factors in HBeAg-negative carriers withpersistently normal serum alanine aminotransferase levels.
Hepatology 2007;45:1193–1198.
[35] Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del
Vecchio E, et al. Updated deﬁnitions of healthy ranges for
serum alanine aminotransferase levels. Ann Intern Med
2002;137:1–10.
[36] Rang A, Bruns M, Heise T, Will H. Antiviral activity of
interferon-alpha against hepatitis B virus can be studied in non-
hepatic cells and is independent of MxA. J Biol Chem
2002;277:7645–7647.
[37] Peters M, Walling DM, Waggoner J, Avigan MI, Sjogren M,
Hoofnagle JH. Immune eﬀects of alpha-interferon in chronic
liver disease. J Hepatol 1986;3:S283–S289.
[38] Perrillo RP, Schiﬀ ER, Davis GL, Bodenheimer Jr HC, Lindsay
K, Payne J, et al. A randomized, controlled trial of interferon
alfa-2b alone and after prednisone withdrawal for the treatment
of chronic hepatitis B. The Hepatitis Interventional Therapy
Group. N Engl J Med 1990;323:295–301.
[39] Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC,
Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): an advance
in the treatment of hepatitis B e antigen-positive chronic hepatitis
B. J Viral Hepat 2003;10:298–305.
[40] Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca
US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in
combination with lamivudine for HBeAg-positive chronic hep-
atitis B: a randomised trial. Lancet 2005;365:123–129.
[41] Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S,
Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the
combination for HBeAg-positive chronic hepatitis B. N Engl J
Med 2005;352:2682–2695.
[42] Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R,
et al. Peginterferon alfa-2a alone, lamivudine alone, and the two
in combination in patients with HBeAg-negative chronic hepa-
titis B. N Engl J Med 2004;351:1206–1217.
[43] Nair S, Perrillo RP. Serum alanine aminotransferase ﬂares
during interferon treatment of chronic hepatitis B: is sustained
clearance of HBV DNA dependent on levels of pretreatment
viremia? Hepatology 2001;34:1021–1026.
[44] Flink HJ, Sprengers D, Hansen BE, van Zonneveld M, de Man
RA, Schalm SW, et al. Flares in chronic hepatitis B patients
induced by the host or the virus? Relation to treatment response
during peg-interferon {alpha}-2b therapy. Gut
2005;54:1604–1609.
[45] van Zonneveld M, Honkoop P, Hansen BE, Niesters HG,
Murad SD, de Man RA, et al. Long-term follow-up of alpha-
interferon treatment of patients with chronic hepatitis B.
Hepatology 2004;39:804–810.
[46] Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P,
et al. Long-term follow-up of patients with chronic hepatitis B
treated with interferon alfa. Gastroenterology
1997;113:1660–1667.
[47] Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm
SW, Janssen HL. Treatment with Peg-interferon alpha-2b for
HBeAg-positive chronic hepatitis B: HBsAg loss is associated
with HBV genotype. Am J Gastroenterol 2006;101:297–303.
[48] Piratvisuth T, Luo K-X, Marcellin P, Chang W-Y, Berg T,
Flisiak R, et al. Eﬀect of ALT ﬂares on eﬃcacy and safety of
peginterferon a-2a (40 kDa) (Pegasys), peginterferon a-2a plus
lamivudine and lamivudine in HBeAg-positive chronic hepatitis
B. J Hepatol 2005;42:189.
[49] Cooksley G, Manns M, Lau G, Liaw Y, Marcellin P, Chow W,
et al. Eﬀect of genotype and other baseline factors on response to
peginterferon a-2a (40 kDa) (Pegasys) in HBeAg-positive
chronic hepatitis B: Results from a large, randomized study. J
Hepatol 2005;42:31.
[50] Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R,
Piratvisuth T, et al. Predicting response to peginterferon alpha-
F. Zoulim, R. Perrillo / Journal of Hepatology 48 (2008) S2–S19 S172a, lamivudine and the two combined for HBeAg-negative
chronic hepatitis B. Gut 2007;56:699–705.
[51] Marcellin P, Bonino F, Lau G, Farci P, Yurdaydin C, Piratvi-
suth T, et al. Virological and biochemical response in patients
with HBeAg-negative CHB treated with peginterferon a-2a
(40 kDa) ± lamivudine: 3-year follow-up results. J Hepatol
2007;46:S25.
[52] Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ.
Long-term follow-up of peginterferon and lamivudine combina-
tion treatment in HBeAg-positive chronic hepatitis B. Hepatol-
ogy 2005;41:1357–1364.
[53] Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM,
et al. A randomized, controlled trial of combination therapy for
chronic hepatitis B: comparing pegylated interferon-alpha2b and
lamivudine with lamivudine alone. Ann Intern Med
2005;142:240–250.
[54] Lutgethetmann M, Wursthorn K, Buggisch P, Zollner B, Zankel
M, Fischer C, et al. 48 weeks of adefovir mono therapy following
48 weeks of combination therapy with peginterferon alpha-2b
and adefovir leads to additional biochemical and virological
improvement. J Hepatol 2007;44:S189.
[55] Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P,
Zollner B, et al. Peginterferon alpha-2b plus adefovir induce
strong cccDNA decline and HBsAg reduction in patients with
chronic hepatitis B. Hepatology 2006;44:675–684.
[56] Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma
BC, et al. Eﬀect of lowering HBV DNA levels by initial antiviral
therapy before adding immunomodulator on treatment of
chronic hepatitis B. Am J Gastroenterol 2007;102:96–104.
[57] Manesis EK, Hadziyannis SJ. Interferon alpha treatment and
retreatment of hepatitis B e antigen-negative chronic hepatitis B.
Gastroenterology 2001;121:101–109.
[58] Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF,
Sablon E, et al. Long-term suppression of hepatitis B e antigen-
negative chronic hepatitis B by 24-month interferon therapy.
Hepatology 2003;37:756–763.
[59] Manesis E, Hadziyannis S, Agelopoulou O, Hadziyannis S.
HBsAg levels under interferon and lamivudine therapy in
HBeAg-negative chronic hepatitis B (CHBe) patients. J Hep-
atol 2005;42:185.
[60] Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of
extended duration peginterferon alfa-2a for patients with hepa-
titis B e antigen-negative chronic hepatitis B. Am J Gastroenterol
2007;102:2718–2723.
[61] Buster EH, Janssen HL. Antiviral treatment for chronic hepatitis
B virus infection – immune modulation or viral suppression?
Neth J Med 2006;64:175–185.
[62] Perrillo RP. Therapy of hepatitis B – viral suppression or
eradication? Hepatology 2006;43:S182–S193.
[63] Zoulim F. Mechanism of viral persistence and resistance to
nucleoside and nucleotide analogs in chronic hepatitis B virus
infection. Antiviral Res 2004;64:1–15.
[64] Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim
F. Inhibitory activity of dioxolane purine analogs on wild-type
and lamivudine-resistant mutants of hepadnaviruses. Hepatology
2002;36:710–722.
[65] Zoulim F, Dannaoui E, Borel C, Hantz O, Lin TS, Liu SH, et al.
20,30-Dideoxy-beta-L-5-ﬂuorocytidine inhibits duck hepatitis B
virus reverse transcription and suppresses viral DNA synthesis in
hepatocytes, both in vitro and in vivo. Antimicrob Agents
Chemother 1996;40:448–453.
[66] Delaney WEt, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, et al.
Intracellular metabolism and in vitro activity of tenofovir against
hepatitis B virus. Antimicrob Agents Chemother
2006;50:2471–2477.
[67] Seigneres B, Aguesse-Germon S, Pichoud C, Vuillermoz I,
Jamard C, Trepo C, et al. Duck hepatitis B virus polymerasegene mutants associated with resistance to lamivudine have a
decreased replication capacity in vitro and in vivo. J Hepatol
2001;34:114–122.
[68] Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro
inhibition of hepadnavirus polymerases by the triphosphates of
BMS-200475 and lobucavir. Antimicrob Agents Chemother
1998;42:3200–3208.
[69] Standring DN, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra
C, et al. Antiviral beta-L-nucleosides speciﬁc for hepatitis B virus
infection. Antivir Chem Chemother 2001;12:119–129.
[70] Delaney WEt, Yang H, Miller MD, Gibbs CS, Xiong S.
Combinations of adefovir with nucleoside analogs produce
additive antiviral eﬀects against hepatitis B virus in vitro.
Antimicrob Agents Chemother 2004;48:3702–3710.
[71] Seigneres B, Martin P, Werle B, Schorr O, Jamard C, Rimsky L,
et al. Eﬀects of pyrimidine and purine analog combinations in the
duck hepatitis B virus infection model. Antimicrob Agents
Chemother 2003;47:1842–1852.
[72] Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al.
A 1-year trial of telbivudine, lamivudine, and the combination in
patients with hepatitis B e antigen-positive chronic hepatitis B.
Gastroenterology 2005;129:528–536.
[73] Sung JJY, Lai J-Y, Zeuzem S, Chow WC, Heathcote EJ, Perrillo
RP, et al. Lamivudine compared with lamivudine and adefovir
dipivoxil for the treatment of HBeAg-positive chronic hepatitis
B. J Hepatol 2008;48:728–735.
[74] Delmas J, Schorr O, Jamard C, Gibbs C, Trepo C, Hantz O,
et al. Inhibitory eﬀect of adefovir on viral DNA synthesis and
covalently closed circular DNA formation in duck hepatitis B
virus-infected hepatocytes in vivo and in vitro. Antimicrob
Agents Chemother 2002;46:425–433.
[75] Kock J, Baumert TF, Delaney WEt, Blum HE, von Weizsacker
F. Inhibitory eﬀect of adefovir and lamivudine on the initiation
of hepatitis B virus infection in primary tupaia hepatocytes.
Hepatology 2003;38:1410–1418.
[76] Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L,
Mason WS. Lack of eﬀect of antiviral therapy in nondividing
hepatocyte cultures on the closed circular DNA of woodchuck
hepatitis virus. J Virol 1997;71:9392–9399.
[77] Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller
DS, et al. Kinetics of hepadnavirus loss from the liver during
inhibition of viral DNA synthesis. J Virol 2001;75:311–322.
[78] Summers J, Mason WS. Residual integrated viral DNA after
hepadnavirus clearance by nucleoside analog therapy. Proc Natl
Acad Sci USA 2004;101:638–640.
[79] Yokosuka O, Omata M, Imazeki F, Okuda K, Summers J.
Changes of hepatitis B virus DNA in liver and serum caused by
recombinant leukocyte interferon treatment: analysis of intrahe-
patic replicative hepatitis B virus DNA. Hepatology
1985;5:728–734.
[80] Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW,
et al. Intrahepatic hepatitis B virus covalently closed circular
DNA can be a predictor of sustained response to therapy.
Gastroenterology 2005;128:1890–1897.
[81] Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K,
Petersen J, Lau G, et al. Persistence of cccDNA during the
natural history of chronic hepatitis B and decline during
adefovir dipivoxil therapy. Gastroenterology
2004;126:1750–1758.
[82] Maynard M, Parvaz P, Durantel S, Chevallier M, Chevallier P,
Lot M, et al. Sustained HBs seroconversion during lamivudine
and adefovir dipivoxil combination therapy for lamivudine
failure. J Hepatol 2005;42:279–281.
[83] Lai CL, Dienstag J, Schiﬀ E, Leung NW, Atkins M, Hunt C,
et al. Prevalence and clinical correlates of YMDD variants
during lamivudine therapy for patients with chronic hepatitis B.
Clin Infect Dis 2003;36:687–696.
S18 F. Zoulim, R. Perrillo / Journal of Hepatology 48 (2008) S2–S19[84] Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiﬀ ER, et al.
Long-term safety of lamivudine treatment in patients with
chronic hepatitis B. Gastroenterology 2003;125:1714–1722.
[85] van Zonneveld M, van Nunen AB, Niesters HG, de Man RA,
Schalm SW, Janssen HL. Lamivudine treatment during preg-
nancy to prevent perinatal transmission of hepatitis B virus
infection. J Viral Hepat 2003;10:294–297.
[86] Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A,
Eisenbach C, et al. Safety and eﬃcacy of lamivudine in patients
with severe acute or fulminant hepatitis B, a multicenter
experience. J Viral Hepat 2006;13:256–263.
[87] Lau GK, He ML, Fong DY, Bartholomeusz A, AuWY, Lie AK,
et al. Preemptive use of lamivudine reduces hepatitis B exacer-
bation after allogeneic hematopoietic cell transplantation. Hepa-
tology 2002;36:702–709.
[88] Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al.
Early is superior to deferred preemptive lamivudine therapy for
hepatitis B patients undergoing chemotherapy. Gastroenterology
2003;125:1742–1749.
[89] Zoulim F, Poynard T, Degos F, Slama A, El Hasnaoui A, Blin P,
et al. A prospective study of the evolution of lamivudine
resistance mutations in patients with chronic hepatitis B treated
with lamivudine. J Viral Hepat 2006;13:278–288.
[90] Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee
WM, et al. Adefovir dipivoxil added to ongoing lamivudine in
chronic hepatitis B with YMDD mutant hepatitis B virus.
Gastroenterology 2004;126:81–90.
[91] Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P,
Rubin R, et al. Adefovir dipivoxil alone or in combination with
lamivudine in patients with lamivudine-resistant chronic hepati-
tis B. Gastroenterology 2004;126:91–101.
[92] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT,
Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of
hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med
2003;348:800–807.
[93] Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiﬀman
ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e
antigen-positive chronic hepatitis B. N Engl J Med
2003;348:808–816.
[94] Durantel S, Werle B, Durantel D, Pichoud C, Currie G, Xiong S,
et al. Diﬀerent proﬁles of response to adefovir dipivoxil and
factors that may inﬂuence response in patients with chronic
hepatitis B. Antiviral Therapy, in press.
[95] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT,
Kitis G, Rizzetto M, et al. Long-term therapy with adefovir
dipivoxil for HBeAg-negative chronic hepatitis B for up to 5
years. Gastroenterology 2006;131:1743–1751.
[96] Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G,
Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-
negative patients developing genotypic resistance to lamivudine.
Hepatology 2005;42:1414–1419.
[97] Lampertico P, Marzano A, Levrero M, Santantonio T, Di
Marco V, Brunetto M, et al. Adefovir and lamivudine combi-
nation therapy is superior to adefovir monotherapy for lamivu-
dine-resistant patients with HBeAg-negative chronic hepatitis B.
Hepatology 2006;44:693A.
[98] Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao
YC, et al. A comparison of entecavir and lamivudine for
HBeAg-positive chronic hepatitis B. N Engl J Med
2006;354:1001–1010.
[99] Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H,
Goodman Z, et al. Entecavir versus lamivudine for patients with
HBeAg-negative chronic hepatitis B. N Engl J Med
2006;354:1011–1020.
[100] Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu
CF, et al. Entecavir resistance is rare in nucleoside naive patients
with hepatitis B. Hepatology 2006;44:1656–1665.[101] Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF,
Cianciara J, et al. Entecavir for treatment of lamivudine-
refractory, HBeAg-positive chronic hepatitis B. Gastroenterol-
ogy 2006;130:2039–2049.
[102] Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA,
Walsh AW, et al. Two-year assessment of entecavir resistance in
lamivudine-refractory hepatitis B virus patients reveals diﬀerent
clinical outcomes depending on the resistance substitutions
present. Antimicrob Agents Chemother 2007;51:902–911.
[103] Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP,
Discotto L, et al. Clinical emergence of entecavir-resistant
hepatitis B virus requires additional substitutions in virus already
resistant to lamivudine. Antimicrob Agents Chemother
2004;48:3498–3507.
[104] Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo
C, et al. Stepwise process for the development of entecavir
resistance in a chronic hepatitis B virus infected patient. J
Hepatol 2007;46:531–538.
[105] McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y,
Wind-Rotolo M, et al. The HBV drug entecavir – eﬀects on
HIV-1 replication and resistance. N Engl J Med
2007;356:2614–2621.
[106] Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon
YM, et al. Treatment of hepatitis B e antigen-positive chronic
hepatitis with telbivudine or adefovir: a randomized trial. Ann
Intern Med 2007;147:745–754.
[107] Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y,
et al. Telbivudine versus lamivudine in patients with chronic
hepatitis B. N Engl J Med 2007;357:2576–2588.
[108] van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A,
Schurmann D, et al. Comparison of adefovir and tenofovir in the
treatment of lamivudine-resistant hepatitis B virus infection.
Hepatology 2004;40:1421–1425.
[109] van Bommel F, Zollner B, Sarrazin C, Spengler U, Huppe D,
Moller B, et al. Tenofovir for patients with lamivudine-resistant
hepatitis B virus (HBV) infection and high HBV DNA level
during adefovir therapy. Hepatology 2006;44:318–325.
[110] Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil
fumarate in patients with HIV and lamivudine-resistant hepatitis
B virus. N Engl J Med 2003;348:177–178.
[111] Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller
MD, et al. Eﬃcacy of tenofovir disoproxil fumarate in antiret-
roviral therapy-naive and -experienced patients coinfected with
HIV-1 and hepatitis B virus. J Infect Dis 2004;189:1185–1192.
[112] Lacombe K, Gozlan J, Boelle PY, Serfaty L, Zoulim F, Valleron
AJ, et al. Long-term hepatitis B virus dynamics in HIV-hepatitis
B virus-co-infected patients treated with tenofovir disoproxil
fumarate. Aids 2005;19:907–915.
[113] Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B,
Brosgart CL, et al. Randomized controlled study of tenofovir
and adefovir in chronic hepatitis B virus and HIV infection:
ACTG A5127. Hepatology 2006;44:1110–1116.
[114] Marcellin P, Buti M, Krastev Z, Germanidis G, Kaita KD,
Kotzev I, et al. A randomized double blind comparison of
tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the
treatment of HBeAg-negative chronic hepatitis B (CHB). Hepa-
tology 2007;46:290A.
[115] Heathcote EJ, Gane E, DeMan R, Lee S, Flisiak R, Manns MP,
et al. A randomized double blind comparison of tenofovir DF
(TDF) versus adefovir dipivoxil (ADV) for the treatment of
HBeAg-positive chronic hepatitis B (CHB). Hepatology
2007;46:861A.
[116] Locarnini S, Hatzakis A, Heathcote J, Keeﬀe EB, Liang TJ,
Mutimer D, et al. Management of antiviral resistance in patients
with chronic hepatitis B. Antivir Ther 2004;9:679–693.
[117] Di Bisceglie AM, Lai CL, Gane E, Chen Y-C, Thongsawat S,
Wang Y, et al. Telbivudine globe trial: maximal early HBV
F. Zoulim, R. Perrillo / Journal of Hepatology 48 (2008) S2–S19 S19suppression is predictive of optimal two-year eﬃcacy in nucle-
oside-treated hepatitis B patients. Hepatology 2006;44:230A.
[118] Keeﬀe EB, Zeuzem S, Koﬀ RS, Dieterich DT, Esteban-Mur R,
Gane EJ, et al. Report of an international workshop: Roadmap
for management of patients receiving oral therapy for chronic
hepatitis B. Clin Gastroenterol Hepatol 2007;5:890–897.
[119] Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG,
Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardiza-
tion of nomenclature and assays and recommendations for
management. Hepatology 2007;46:254–265.
[120] Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L,
et al. Early detection of viral resistance by determination of
hepatitis B virus polymerase mutations in patients treated by
lamivudine for chronic hepatitis B. Hepatology
2000;32:1078–1088.
[121] Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters
KA, Tyrrell DL, et al. Identiﬁcation and characterization of
mutations in hepatitis B virus resistant to lamivudine. Lamivu-
dine clinical investigation group. Hepatology 1998;27:1670–1677.
[122] Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WEt.
Cross-resistance testing of next-generation nucleoside and nucle-
otide analogues against lamivudine-resistant HBV. Antivir Ther
2005;10:625–633.
[123] Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C,
et al. Resistance to adefovir dipivoxil therapy associated with the
selection of a novel mutation in the HBV polymerase. Gastro-
enterology 2003;125:292–297.
[124] Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S,
Brosgart CL, et al. Selection of a hepatitis B virus strain resistant
to adefovir in a liver transplantation patient. J Hepatol
2003;39:1085–1089.
[125] Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection
of a multiple drug-resistant hepatitis B virus strain in a liver-
transplanted patient. Gastroenterology 2006;131:1253–1261.
[126] Qi X, Xiong S, Yang H, Miller M, Delaney WEt. In vitro
susceptibility of adefovir-associated hepatitis B virus polymerase
mutations to other antiviral agents. Antivir Ther
2007;12:355–362.
[127] Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann
H, et al. Variant of hepatitis B virus with primary resistance to
adefovir. N Engl J Med 2006;354:1807–1812.
[128] Curtis M, Zhu Y, Borroto-Esoda K. Hepatitis B virus containing
the I233V mutation in the polymerase reverse-transcriptasedomain remains sensitive to inhibition by adefovir. J Infect Dis
2007;196:1483–1486.
[129] Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M,
Tacke F, et al. Selection of hepatitis B virus polymerase
mutations in HIV-coinfected patients treated with tenofovir.
Antivir Ther 2005;10:727–734.
[130] Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS.
Evolution of multi-drug resistant hepatitis B virus during
sequential therapy. Hepatology 2006;44:703–712.
[131] Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carro-
uee-Durantel S, Villeneuve JP, et al. Susceptibility to antivirals
of a human HBV strain with mutations conferring resistance
to both lamivudine and adefovir. Hepatology
2005;41:1391–1398.
[132] Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E,
Colombo M. Low resistance to adefovir combined with lamivu-
dine: a 3-year study of 145 lamivudine-resistant hepatitis B
patients. Gastroenterology 2007;133:1445–1451.
[133] Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res
2006;71:206–215.
[134] Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL.
Hepatitis B virus DNA levels at week 4 of lamivudine treatment
predict the 5-year ideal response. Hepatology
2007;46:1695–1703.
[135] Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim
F, Leroux-Roels G, et al. Line probe assay for monitoring drug
resistance in hepatitis B virus-infected patients during antiviral
therapy. J Clin Microbiol 2000;38:702–707.
[136] Clavel F, Hance AJ. HIV drug resistance. N Engl J Med
2004;350:1023–1035.
[137] Hui C-K, Zhang H-Y, Bowden S, Locarnini S, Luk JM, Leung
K-W, et al. 96 weeks combination of adefovir dipivoxil plus
emtricitabine vs. adefovir dipivoxil monotherapy in the treat-
ment of chronic hepatitis B. J Hepatol 2008;48:714–720.
[138] Litwin S, Toll E, Jilbert AR, Mason WS. The competing roles of
virus replication and hepatocyte death rates in the emergence of
drug-resistant mutants: theoretical considerations. J Clin Virol
2005;34:S96–S107.
[139] Brunelle MN, Lucifora J, Neyts J, Villet S, Holy A, Trepo C,
et al. In vitro activity of 2,4-diamino-6-[2-(phosphonometh-
oxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B
virus mutants. Antimicrob Agents Chemother 2007;51:
2240–2243.
